Literature DB >> 11304034

Tissue sphinganine as a biomarker of fumonisin-induced apoptosis.

R R Delongchamp1, J F Young.   

Abstract

NCTR measured sphinganine concentrations in the livers of mice and in the livers and kidneys of rats in conjunction with a tumour bioassay. In our model of the tumour incidence, target-tissue levels of sphinganine serve as a biomarker for a dose response of fumonisin B1 on cell death. Initially we questioned the utility of sphinganine levels in this role because they were highly variable when compared across time points. In spite of this concern, a conceptual framework and data are presented that support the use of sphinganine as a biomarker for a dose response of fumonisin B1 on cell death. This framework is reasonably consistent with observed sphinganine concentrations in the examined tissues, the literature on fumonisin's effects on sphingolipid synthesis, and our hypothesized mechanism through which fumonisin B1 increases age-specific tumour incidence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11304034     DOI: 10.1080/02652030118953

Source DB:  PubMed          Journal:  Food Addit Contam        ISSN: 0265-203X


  7 in total

1.  Fumonisin B1 and risk of hepatocellular carcinoma in two Chinese cohorts.

Authors:  E Christina Persson; Vikash Sewram; Alison A Evans; W Thomas London; Yvette Volkwyn; Yen-Ju Shen; Jacobus A Van Zyl; Gang Chen; Wenyao Lin; Gordon S Shephard; Philip R Taylor; Jin-Hu Fan; Sanford M Dawsey; You-Lin Qiao; Katherine A McGlynn; Christian C Abnet
Journal:  Food Chem Toxicol       Date:  2011-11-29       Impact factor: 6.023

2.  Risk-assessment implications of mechanistic model's prediction of low-dose nonlinearity of liver tumor risk for mice fed fumonisin b(1).

Authors:  Ralph L Kodell; Angelo Turturro
Journal:  Nonlinearity Biol Toxicol Med       Date:  2004-01

Review 3.  Mycotoxin-Linked Mutations and Cancer Risk: A Global Health Issue.

Authors:  Theodora Ekwomadu; Mulunda Mwanza; Alfred Musekiwa
Journal:  Int J Environ Res Public Health       Date:  2022-06-24       Impact factor: 4.614

4.  Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: a novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals.

Authors:  Nicholas C Zitomer; Trevor Mitchell; Kenneth A Voss; Genevieve S Bondy; Sarah T Pruett; Ethel C Garnier-Amblard; Lanny S Liebeskind; Hyejung Park; Elaine Wang; M Cameron Sullards; Alfred H Merrill; Ronald T Riley
Journal:  J Biol Chem       Date:  2008-12-18       Impact factor: 5.157

5.  The African Fusarium/maize disease.

Authors:  Michael F Dutton
Journal:  Mycotoxin Res       Date:  2009-01-14       Impact factor: 3.833

6.  Validation of fumonisin biomarkers in F344 rats.

Authors:  Qingsong Cai; Lili Tang; Jia-Sheng Wang
Journal:  Toxicol Appl Pharmacol       Date:  2007-08-16       Impact factor: 4.219

7.  Evaluation of sphingolipids in Wistar rats treated to prolonged and single oral doses of fumonisin b₁.

Authors:  Glória M Direito; Adriana P Almeida; Simone Aquino; Tatiana Alves Dos Reis; Claudia Rodrigues Pozzi; Benedito Corrêa
Journal:  Int J Mol Sci       Date:  2008-12-27       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.